• 제목/요약/키워드: Chronic Hepatitis B

검색결과 247건 처리시간 0.025초

Elimination of Mother-to-Infant Transmission of Hepatitis B Virus: 35 Years of Experience

  • Lu, Fang-Ting;Ni, Yen-Hsuan
    • Pediatric Gastroenterology, Hepatology & Nutrition
    • /
    • 제23권4호
    • /
    • pp.311-318
    • /
    • 2020
  • Chronic hepatitis B viral (HBV) infection remains a major health threat, especially in high-prevalence areas. Most infants infected by mother-to-infant HBV transmission become chronic carriers. In Taiwan, many important preventive interventions have been implemented to block the perinatal transmission of HBV in the past 35 years. The first nationwide universal HBV vaccination program was launched in Taiwan in July 1984. The three-dose HBV vaccine completion rate reached 98.1% in 2018. The prevalence of Hepatitis B surface antigen (HBsAg) decreased from 9.8% in pre-vaccinated period in 1984 to 0.5% in the vaccinated cohort in 2014. The incidence of hepatocellular carcinoma in children aged 6-9 years significantly declined from 0.52 to 0.13 per 100,000 children born before and after 1984, respectively. Furthermore, we have performed a maternal HBV screening program during pregnancy since 1984, with the screening rate peaked at 93% in 2012. The HBsAg- and HBeAg-seropositive rate in pregnant women declined from 13.4% and 6.4% in 1984-1985 to 5.9% and 1.0% in 2016, respectively. To closely control perinatal HBV infection, we have administered hepatitis B immunoglobulin immediately after birth and checked the serum level of HBsAg and anti-HBs in high-risk babies born to HBsAg-seropositive mothers, irrespective of their HBeAg status, since July 2019. We have also adopted short-term antiviral treatments such as tenofovir 300 mg daily in the third trimester for highly viremic mothers and reduced the perinatal infection rates from 10.7 to 1.5%. Through all these efforts, we expect to meet the global goal of eliminating HBV infection by 2030.

B형 간염 바이러스(Hepatitis B Virus)에 의한 신장병증 1예 (A Case of Hepatitis B Virus Associated Nephropathy)

  • 김태년;이영곤;윤경우;김종설
    • Journal of Yeungnam Medical Science
    • /
    • 제3권1호
    • /
    • pp.325-332
    • /
    • 1986
  • 저자들은 16세 남자 환자에서 만성 지속성 간염 및 막증식성 사구체신염(type I)이 발생한 Hepatitis B virus associated nephropathy 1예(例)를 경험하였기에 보고하는 바이며, 특히 우리나라는 B형 간염 바이러스의 나환율(羅患率)이 높기 때문에 B형 간염과 연관된 신질환의 빈도도 높을 것으로 추정(推定)되며, 그 중요성도 클 것으로 사료(思料)된다. 따라서 향후(向後) Hepatitis B virus associated nephropathy의 발생 기전 및 치료법에 관한 체계적인 연구가 필요할 것으로 생각된다.

  • PDF

바이러스성 간질환 치료약 (Drugs for the Treatment of Viral Hepatitis)

  • 김충섭
    • 약학회지
    • /
    • 제57권1호
    • /
    • pp.43-54
    • /
    • 2013
  • Viral hepatitis is the inflammation of liver cells caused by viruses, and still one of the major health-care problems worldwide. A number of viruses to cause hepatitis are type A, B, C, D, E or G. Among these viruses leading to hepatitis, B and C are more troublesome being more prone to chronic illness which can cause the potentially fatal conditions of hepatocellular carcinoma (HCC) and/or liver failure. If immediate treatment is not initiated, liver transplant is the only option left. Over the past few decades there has been remarkable progress in diagnose and monitor all hepatitis virus infections for treatment and prevention. Nonetheless, important challenges remain to develop more effective and safe vaccines for prevention as well as antiviral agents to reduce viremia/viral load by inhibiting viral replication. The development and evaluation of antiviral agents through carefully designed clinical trials over the last 25 years has heralded a new dawn in the treatment of patients chronically infected with the hepatitis B and C viruses, but not so for the D virus. The introduction of Direct Acting Antivirals (DDAs) for the treatment of HBV carriers has permitted the long term use of these compounds for the continuous suppression of viral replication. This review aims to summarize the current status and development approaches of antiviral drugs for the treatment of viral hepatitis and future perspectives.

만성 B형 바이러스성 간질환의 예방 교육매체 프로그램 개발 (Development of Educational Materials for Management and Prevention of Chronic Hepatitis)

  • 신계영;이선옥;김매자
    • 지역사회간호학회지
    • /
    • 제13권3호
    • /
    • pp.503-512
    • /
    • 2002
  • Purpose: This study was conducted to develop educational materials for preventing type B viral hepatitis infection. Prior to this study, a survey had been conducted to define the educational needs of persons with hepatitis B antigen. Method: Based on the results of the former study and a review of the literature, the content of the educational materials was confined to the transmission cycle and its prevention in type B hepatitis. A professional team that consisted of writers and producers videotaped the lectures provided by professors and instructors in a nursing school. A professional graphic designer produced the leaflet to enhance the visual effects. Results: The contents of the educational materials for type B hepatitis were composed of six parts: (1) the prevalence rate (or morbidity) of type B hepatitis antigen positive and its recent trend, (2) transformation of hepatitis. (3) transmission cycle of hepatitis infection, (4) persons who are susceptible to hepatitis and need a vaccination, (5) preventive approach hepatitis vaccination and the guideline for patients' daily lives for preventing infection and (6) questions and answers. The materials were delivered in the form of lectures, visual charts, graphics, and multi-media. Conclusion: The educational materials developed in this study may provide practical information and knowledge on strategies to prevent type B hepatitis. The educational materials may be utilized in primary health care centers or school health services.

  • PDF

Virological Characteristics in Chronic Hepatitis B Patients with Concurrent HBsAg and anti-HBs Positivity

  • Lee, Hyeok-Jae;Lee, Min-Hyeok
    • 대한의생명과학회지
    • /
    • 제18권3호
    • /
    • pp.283-290
    • /
    • 2012
  • In this study, we investigated the virological characteristics, HBV DNA levels and presence of mutations of "a" determinant in the HBsAg S gene in chronic hepatitis B patients with coexisting HBsAg and anti-HBs. The 18 patients who were diagnosed with chronic hepatitis B were both positive for HBsAg and anti-HBs. HBV Among them, 15 patients were DNA positive. The median of HBV DNA levels in serum was $2.18{\times}10^7$ copies/mL with the HBsAg+/anti-HBsAb+ patients. Also, 4 of 8 HBeAg negative patients had HBV DNA levels higher than $10^4$ copies/mL and the median of HBV DNA levels was $2.03{\times}10^6$ copies/mL, which were significantly high. These results showed that viral replication still existed in most of the patients of the concomitant HBsAg and anti-HBs, and even in the some HBeAg negative patients. Furthermore, mutation within the "a" determinant of HBV were found in 7 of 15 patients. The most frequent changes were located at positions aa126. In addition, one mutation observed for HBsAg only positive.

Recovery of NK(CD56+CD3-) Cells after One Year of Tenofovir Therapy for Chronic Hepatitis B Infection

  • Lee, Hwan Hee;Kang, Hyojeung;Cho, Hyosun
    • Journal of Microbiology and Biotechnology
    • /
    • 제27권6호
    • /
    • pp.1204-1208
    • /
    • 2017
  • Natural killer (NK) cells have been reported to be dysfunctional in chronic hepatitis B (CHB) infection. However, the functional recovery of NK cells under antiviral therapeutic agents in CHB was not clearly understood. In this study, we investigated the phenotypic changes of NK(CD56+CD3-) cells in terms of their functional markers (CD16, NKG2A, NKG2D) during tenofovir therapy in CHB. The frequency of NK(CD56+CD3-) cells in CHB patients was significantly increased after 12 months of tenofovir therapy when compared with baseline. The expression levels of CD16+/CD56+CD3- and NKG2A+/CD56+CD3- cells were also affected by tenofovir treatment. In addition, there was a positive correlation between the proportion of NK(CD56+CD3-) cells and HBV DNA (log copies/ml) in CHB patients.

한국형 출혈열 및 만성간염과 조직적합성 항원간의 유전적 관련성에 관한 연구(II) -(II) 만성간염과 조직적합성 항원간의 유전적 관련성에 관한 연구- (Study on the Genetic Relationship between Korean Hemorrhagic Fever, Chronic Hepatitis and Histocompatibility Antigens(II) -(II) Study on the Genetic Relationship between Chronic Hepatitis and Histocompatibility Antigens-)

  • 한훈;김태규;유문간;임병욱;김금용;이종훈;김부성;김호연;윤영석;방병기;민병석;김한화;박희봉
    • 대한미생물학회지
    • /
    • 제21권2호
    • /
    • pp.233-241
    • /
    • 1986
  • Patients of chronic hepatic diseases(n=107) including chronic hepatitis caused by hepatitis B virus infections(n=31), liver cirrhosis(n=53), and hepatocellular carcinoma(n=23) were examined to ascertain genetic relationship between chronic hepatic diseases and histocompatibility antigen. Peripheral blood lymphocytes were separated from whole blood by the method of Ficoll/Hypaque gradient. Total 54 histocompatibility antigens(class I antigens: 41, class II antigens: 13) were analysed by performing of complement dependent microlymphocytotoxicity method using Terasaki's and Catholic Medical College tissue typing plates. HLA antigen frequencies were compared with those of 661 normal controls. The following results were obtained: 1. HLA antigen frequencies of HLA-Bw46, -Bw76, -Cw1, -Cw6, and HLA-DR8 in chronic hepatitis patients were shown to be higher than those in controls(P<0.01). 2. HLA antigen frequencies of HLA-Bw46, -Cw7(P<0.01), and HLA-B37, -Bw58, -Cw1, -MT1(P < 0.05) in liver cirrhosis patients were shown relatively higher frequencies than those in controls. 3. In patients with hepatocellular carcinoma, antigens of HLA-A1, -A26, -Cw3, -Cw7 and HLA-DR6 were dominantly detected. 4. There were negative associations with HLA-Cw4, and -DR4 in patients of chronic hepatic diseases(P < 0.05).

  • PDF

Serotyping in Patients with Chronic Hepatitis C

  • Soon-Mo Chang
    • 대한의생명과학회지
    • /
    • 제9권4호
    • /
    • pp.209-214
    • /
    • 2003
  • To determine the clinical usefulness of Immuno Blot test, 160 samples from the patients with chronic HCV infection were analyzed. And serotyping and line probe assay were performed to evaluate the distribution of hepatitis C virus genotypes in Korean isolates. In this group, as a result of genotyping type 1 band 2a, the serotype I and II were the most common source of HCV infection. There were no significant difference in response to the alpha-interferon HCV infection treatment with the subtype 1 b or 2a. And the serotypes of NS4 peptides were compared with the genotypes to evaluate their clinical usefulness. Among 49 cases studied for genotypes and serotype, genotype 1 b, 1 b/2b, 2a, 2a/2c and 2b were 51.0%, 2.0%, 34.6%, 8.1% and 4.0%, respectively. The serotypes I and II were 57.1% and 42.8%, respectively; they were matched with genotypes in 85.7% and seemed to be easy to perform. To monitor their performing progress or treatment response, serotype test was made before the genotype test. The Result showed that there was no significant difference in response to the alpha-interferon HCV infection treatment with the subtype 1 b or 2a in Korea.

  • PDF

The KIF1B (rs17401966) Single Nucleotide Polymorphism is not Associated with the Development of HBV-related Hepatocellular Carcinoma in Thai Patients

  • Sopipong, Watanyoo;Tangkijvanich, Pisit;Payungporn, Sunchai;Posuwan, Nawarat;Poovorawan, Yong
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제14권5호
    • /
    • pp.2865-2869
    • /
    • 2013
  • Hepatitis B virus (HBV) infection can become chronic and if left untreated can progress to hepatocellular carcinoma (HCC).Thailand is endemic for HBV and HCC is one of the top five cancers, causing deaths among Thai HBV-infected males. A single nucleotide polymorphism (SNP) at the KIF1B gene locus, rs17401966, has been shown to be strongly associated with the development of HBV-related HCC. However, there are no Thai data on genotypic distribution and allele frequencies of rs17401966. Thai HBV patients seropositive for HBsAg (n=398) were therefore divided into two groups: a case group (chronic HBV with HCC; n=202) and a control group (HBV carriers without HCC; n=196). rs17401966 was amplified by polymerase chain reaction (PCR) and analyzed by direct nucleotide sequencing. The genotypic distribution of rs174019660 for homozygous major genotype (AA), heterozygous minor genotype (AG) and homozygous minor genotype (GG) in the case group was 49.5% (n=100), 40.1% (n=81) and 10.4% (n=21), respectively, and in controls was 49.5% (n=97), 42.3% (n=83) and 8.2% (n=16). Binary logistic regression showed that rs17401966 was not statistically associated with the risk of HCC development in Thai chronic HBV patients (p-value=0.998, OR=1.00 and 95% CI=0.68-1.48). In conclusion, the KIF1B gene SNP (rs174019660) investigated in this study showed no significant association with HBV-related HCC in Thai patients infected with HBV, indicating that there must be other mechanisms or pathways involved in the development of HCC.

Prevalence of Hepatitis B Virus Infection in Kaifeng, China: A 5-year Observation

  • Zhang, Jinli;Ma, Chunyan;Li, Hang;Steele, Michael;Idris, Adi
    • 한국미생물·생명공학회지
    • /
    • 제46권4호
    • /
    • pp.430-433
    • /
    • 2018
  • Hepatitis B is a major health problem in China. However, little is known about the prevalence of hepatitis B virus (HBV) in Kaifeng, the major urban capital of Henan province, China. We found that HBV prevalence increased with age and that chronic HBV was predominant in adult males in Kaifeng. The HBV prevalence remained unchanged over a 5-year period for all age groups. Alarmingly, 25% of the population remained unvaccinated and potentially susceptible to future HBV infection. HBV immunization and health education initiatives should be carried out in this population to further reduce the overall prevalence of HBV.